Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02524041
Other study ID # 1308046
Secondary ID 130560B-22
Status Completed
Phase N/A
First received August 13, 2015
Last updated May 24, 2016
Start date March 2014
Est. completion date April 2016

Study information

Verified date May 2016
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

Based on the evidence that periostin is specifically involved in intra-cortical remodeling control, our working hypothesis is that assessment of its concentration in the serum would be helpful in identifying patients with severe cortical porosity, a critical parameter in bone fragility. Periostin expression by osteoblasts and osteocytes is part of the bone cortical response to anabolic stimuli such as mechanical strain or intermittent increase in parathyroid hormone. However, it remains unknown whether this expression may participate as well to mechanisms that will lead to exaggerated intra-cortical remodeling and subsequent bone loss.

In rare clinical situations in which trans-iliac bone biopsies will be necessary to better understand their bone status in addition to densitometry and biological bone markers assessment, specific analyses using immune-staining techniques will be performed on the bone sample. Data from routine follow-up every six months will be also collected in this specific sub-group.

High resolution peripheral quantitative computerized tomography (HR-pQCT) gives the opportunity of performing a virtual bone biopsy providing information on trabecular and cortical microarchitecture in vivo. These microarchitectural parameters allow a more accurate evaluation of the alteration of the bone structure and therefore of the fracture risk as compared to current tools used in clinical practice such as densitometry. However, the availability of such HRpQCT facilities is limited and there is on-going development on the best way of measuring porosity for example. The definition of a biological profile including key proteins such as periostin and sclerostin involved in porosity mechanisms is therefore of great interest. A better understanding of the relationship between bone matrix components and parathyroid hormone effects also appears as critical. Follow-up of routine evaluation parameters reflecting bone status in a subgroup of specific patients could also provide new and additional information.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Hyperparathyroidism defined by a parathyroid hormone serum level above 65 ng/ml, secondary to Chronic Kidney Disease (CKD) ou vitamin D deficiency

Exclusion Criteria:

- Concurrent bone disease (such as Paget's disease, osteomalacia),

- Other endocrinopathy having an impact on bone metabolism (such as Cushing, hyperthyroidism, severe hypogonadism (except menopause)),

- Current or previous bisphosphonate treatment.

- Transplantation

- parathyroidectomy

- Life expectancy less than 3 months.

- Lack of study understanding.

- Lack of agreement.

- Under legal control.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Device:
HR-pQCT
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
Other:
blood specimen
blood specimen

Locations

Country Name City State
France CHU de SAINT-ETIENNE Saint-etienne

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne University Hospital, Geneva

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between periostin level and cortical porosity Correlation between periostin serum level (ng/ml) and cortical porosity. Cortical porosity (%) is measured by HR-pQCT day 1 No
Secondary Correlation between periostin level and other trabecular and cortical microarchitectural parameters (composite outcome) Correlation between periostin serum level (ng/ml) and other trabecular and cortical microarchitectural parameters. Cortical microarchitectural parameters are a composite measure measured by HR-pQCT. The measures are : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA), Cortical volumetric mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm), Cortical thickness (mm), Trabecular spacing (mm)
o Trabecular distribution (mm)
day 1 No
Secondary Correlation between parathyroid hormon level and other trabecular and cortical microarchitectural parameters (composite outcome) Correlation between parathyroid hormon serum level (pg/ml) and other trabecular and cortical microarchitectural parameters. Cortical microarchitectural parameters are a composite measure measured by HR-pQCT. The measures are : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA), Cortical volumetric mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm), Cortical thickness (mm), Trabecular spacing (mm)
o Trabecular distribution (mm)
day 1 No
Secondary Correlation between Sclerostin serum level and cortical porosity Correlation between Sclerostin serum level (ng/ml) and cortical porosity.Cortical porosity (%) is measured by HR-pQCT. Day 1 No
Secondary Correlation between parathyroid hormon level and cortical porosity Correlation between parathyroid hormon serum level (pg/ml) and cortical porosity.Cortical porosity (%) is measured by HR-pQCT. Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00377312 - 7 Day Continuous Parathyroid Hormone IV Infusion Phase 0
Completed NCT04040946 - Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Phase 3
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Completed NCT01691781 - The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study N/A
Completed NCT00538720 - Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT) Phase 1
Completed NCT00887666 - Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure N/A
Terminated NCT03044600 - Gene Expression in Hyperparathyroidism
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT01872429 - Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients N/A
Completed NCT00800358 - Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism N/A
Recruiting NCT00169806 - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis N/A
Completed NCT03968510 - Swalqol in Primary Hyperparathyroidism
Completed NCT00501215 - Effect of Parathyroidectomy on Sleep N/A
Completed NCT02591160 - Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism N/A
Recruiting NCT05299632 - F-18 PSMA for Localization of Parathyroid Adenoma
Recruiting NCT02986607 - Corticosteroid Rhythms in Hypoparathyroid Patients Early Phase 1
Completed NCT02432599 - Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas Phase 2
Recruiting NCT05667090 - Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients N/A